ThromboGenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps?

With U.S. sales of its eye drug Jetrea lagging, ThromboGenics is casting about for "strategic options." The company boasts Novartis' ($NVS) Alcon unit as a marketing partner outside the U.S. but has been going it alone in the States. Is another partnership in the offing? Release | Report

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.